

- Cardiac magnetic resonance imaging (CMR)  
(*Cont.*):  
in valvular heart disease, 270e-6  
in ventricular tachycardia, 1491, 1493f
- Cardiac mass, 270e-23–24, 270e-23f. *See also*  
Cardiac tumors
- Cardiac murmurs. *See* Heart murmurs
- Cardiac output  
calculation and normal values, 1748t  
control of, **265e-7**  
measurement of, 1462–1463  
in pregnancy, 45  
in sepsis/septic shock, 1755  
in shock, 1729, 1745, 1747, 1748t
- Cardiac resynchronization therapy, 273e-7, 1514
- Cardiac risk assessment, 51–53, 52f, 52t, 53f, 53t
- Cardiac-specific troponins. *See* Troponins
- Cardiac stem cells, 453t
- Cardiac syncope  
in arrhythmias, 145t, 146–147, 273e-4, 273e-5  
ECG in, 148  
pattern of, 1439  
in structural heart disease, 145t, 147  
treatment of, 147
- Cardiac tamponade, **1573**  
cardiogenic shock in. *See* Cardiogenic shock  
clinical features of, 1573, 1573t  
diagnosis of, 1574  
differential diagnosis of, 1462, 1463t, 1573t, 1762t  
dyspnea in, 47e-2  
ECG in, 1458, 1459f, 1573, 1573t  
low-pressure, 1574  
malignant, 1788–1789  
paradoxical pulse in, 1574  
pathophysiology of, 1573  
treatment of, 1574
- Cardiac thrombus, 270e-23, 270e-23f
- Cardiac transplantation, **1516**  
contraindications to, 1517  
donor allocation system for, 1516–1517  
global considerations in, 1516  
immunosuppression for, 1517, 2764t, 2766t  
indications for, 1517  
LVADs as bridge to, 1518–1519, 1519f  
posttransplant complications  
allograft CAD, 1517–1518  
infection, 924t, 926, 1518  
malignancy, 1518  
results of, 1517, 1517f  
surgical technique, 1516
- Cardiac trauma, **289e-3**  
aortic rupture in, 289e-3, 1637  
blunt, 289e-3  
myocardial contusions, 289e-3  
nonpenetrating, 289e-3  
penetrating, 289e-3  
pericarditis following, 1575  
treatment of, 289e-3
- Cardiac tumors, **289e-1**  
benign, 289e-1–2  
clinical features of, 289e-1–2  
CMR in, 289e-2f  
echocardiography in, 270e-23–24, 270e-24f, 289e-1f  
metastatic, 270e-24, 271e-8f, 271e-8v, 289e-2  
primary, 270e-24, 289e-1–2. *See also* Myxoma sarcoma, 289e-2
- Cardiobacterium hominis*, 183e-1, 183e-2t
- Cardioembolic stroke, 2563–2564. *See also*  
Ischemic stroke
- Cardio-fascio-cutaneous syndrome, 436t
- Cardiogenic shock, **1759**  
clinical features of, 1760  
compressive, **1750**  
diagnosis of, 1759–1760, 1761f  
etiology of, 1759, 1760t  
in free wall rupture, 1762  
hemodynamic patterns in, 1762t  
iatrogenic, 1764  
incidence of, 1759  
in mitral regurgitation, 1762  
in myocardial infarction, 1608  
in myocarditis, 1762  
pathophysiology of, 1759, 1759f  
patient profile in, 1759  
physiologic characteristics of, 1748t  
prognosis of, 1762  
in right ventricular failure, 1762  
timing of, 1759  
treatment of, 1760–1762, 1761f  
in ventricular septal rupture, 1762
- Cardiolipin, 372e-24t, 406
- Cardiomyocytes, 90e-2, 265e-5, 265e-5f
- Cardiomyopathy, **1553**  
cardiac arrest risk factors in, 1767  
cardiogenic shock in. *See* Cardiogenic shock  
in Chagas disease, 1395, 1396  
classification of, 1553, 1554t  
clinical features of, 1553, 1554t  
definition of, 1553  
dilated. *See* Dilated cardiomyopathy  
dyspnea in, 47e-2  
genetic considerations in, 1553–1556, 1555t, 1556f  
HIV-associated, 1255, 1560  
hypertrophic. *See* Hypertrophic cardiomyopathy  
idiopathic, 1565  
initial evaluation of, 1554t  
iron-overload, 270e-21, 270e-27v  
ischemic, 1580  
in low- and middle-income countries, 15–16  
in metabolic disorders, 1565–1566  
overlapping types of, 1558t, 1565–1566  
peripartum, 47, 1562  
radiation-related, 1567  
restrictive. *See* Restrictive cardiomyopathy  
in rheumatoid arthritis, 2138  
syncope in. *See* Cardiac syncope  
Takotsubo (stress-related), 97, 289e-3, 1565  
ventricular tachycardia in, 1495, 1495t, 1498
- Cardiopulmonary bypass  
acute kidney injury and, 1802–1803  
brain injury after, 463e-2–3, 463e-2f  
platelet dysfunction in, 730  
for rewarming, 478e-3t
- Cardiopulmonary resuscitation, 66, 478e-2, 1768
- Cardiorenal syndrome, 1508
- Cardiovascular collapse, 1764, 1765t. *See also*  
Cardiac arrest
- Cardiovascular disease  
in alcohol use disorder, 2725  
in amyloidosis, 721, 722  
in Andersen-Tawil syndrome, 462e-18  
approach to the patient, **1439**  
arrhythmias in. *See* Cardiac arrhythmias  
biology of, **265e-1**  
in carcinoid syndrome, 564–565, 564–567  
cardiac symptoms in, 1439  
congenital. *See* Congenital heart disease (CHD)  
coronary artery. *See* Coronary artery disease (CAD)  
cyanosis in, 249  
deaths from, 56t, 467  
estimated 2010–2030, 266e-3t  
vs. other causes, 266e-2f  
by race and Hispanic origin, 16e-1f  
by sex, 6e-1t  
in women, 6e-1t, 6e-2f  
worldwide by income group, 11t, 266e-3, 266e-3f  
worldwide by region, 266e-4, 266e-4f
- depression in, 2714  
in diabetes mellitus, 290e-1, 290e-1t  
atherosclerosis, 291e-6–7  
autoimmune pancreatitis and, 2099  
cardiomyopathy, 1563  
global considerations in, 266e-4  
ischemic heart disease, 1587  
morbidity and mortality data, 2427  
risk factors for, 2428  
treatment and prevention of, 2427–2428
- diagnosis of, 1439–1440  
imaging tests for. *See* Cardiac imaging  
physical examination. *See* Cardiovascular system, physical examination of
- pitfalls in, 1440–1441  
in women vs men, 6e-2–3  
diet and, 266e-4  
dyspnea in, 47e-1t, 47e-2, 47e-2t  
edema in, 251–252, 252t  
epidemiologic transition of, 266e-1–2, 266e-1t  
epidemiology of, **266e-1**, 266e-3, 266e-3f  
erectile dysfunction in, 326  
exercise and, 266e-4  
family history in, 1440  
functional classification of, 1439–1440, 1440t, 1501, 1501t, 1581t  
gene therapy in, 91e-2f, 91e-4  
genetic considerations in, 291e-10  
global burden of, 11t, 15–16, 266e-2–3, 266e-3f, 266e-3t  
heart failure. *See* Heart failure (HF)  
in hemochromatosis, 270e-21, 290e-1t, 1471, 1564, 2517  
hypercholesterolemia and, 266e-4  
in hypothermia, 478e-2t  
in IBD, 1959  
immunizations recommendations for, 788f  
infections in cancer patient, 489  
ischemic. *See* Ischemic heart disease  
ischemic stroke in, 2564, 2566t  
in Kearns-Sayre syndrome, 462e-15  
as late consequence of cancer/cancer therapy, 621, 1562–1563  
in low- and middle-income countries, 11t, 15–16  
in megaloblastic anemia, 643  
metabolic syndrome and, 1439, 2450  
in muscular dystrophy, 462e-6, 462e-9, 462e-10  
myocardial infarction. *See* Myocardial infarction (MI)  
natural history of, 1439  
obesity and, 266e-4, 415e-6  
in Paget's disease of bone, 426e-2  
in pregnancy, 46–47  
prevention of, 17, 266e-4–5, 1441  
pulmonary edema in, 47e-4  
rheumatic. *See* Rheumatic fever, cardiovascular complications of  
in rheumatoid arthritis, 2138  
risk factors for, 266e-4, 291e-4, 291e-6t, 2725. *See also* Atherosclerosis  
in sarcoidosis, 2208  
in SLE, 27, 2129t  
smoking and, 266e-4, 2729–2730, 2730t  
syncope in. *See* Cardiac syncope  
in syphilis. *See* Syphilis, secondary  
in systemic sclerosis, 2158, 2162  
testosterone therapy and, 2373–2374  
tissue engineering strategies in, 92e-2, 92e-3v  
in travelers, 799  
treatment of, 1441  
valvular. *See* Valvular heart disease  
in women, 6e-1t, 6e-2–3, 6e-2f
- Cardiovascular system  
biology of, **265e-1**  
assessment of cardiac function, 265e-9–11, 265e-10f  
blood vessels. *See* Blood vessels  
cardiac contraction. *See* Cardiac contraction  
control of cardiac performance and output, 265e-7–8, 265e-9f, 265e-9t  
developmental, 265e-11–12, 265e-11f  
gut microbiota and, 86e-7  
in hypoxia, 247  
imaging of. *See* Cardiac imaging  
physical examination of, **1442**  
abdomen, 1443  
approach to, 1442  
arterial pulses, 1445–1446, 1445f, 1446f  
blood pressure, 1444–1445  
cardiac auscultation  
dynamic, 1449–1450, 1450t  
heart murmurs, 1448–1449, 1448f, 1449f. *See also* Heart murmurs  
heart sounds, 1447–1448, 1447f. *See also* Heart sounds  
in pericardial disease, 1450  
of prosthetic valves, 1450